Catalent Inc. (NYSE:CTLT) Receives $27.80 Average PT from Brokerages
Catalent Inc. (NYSE:CTLT) has received a consensus rating of “Hold” from the ten analysts that are presently covering the company. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.80.
Several research analysts recently commented on the stock. Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Tuesday, June 21st. Jefferies Group lifted their target price on shares of Catalent from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Thursday. Finally, Bank of America Corp. raised shares of Catalent from a “neutral” rating to a “buy” rating in a research note on Monday, June 20th.
Hedge funds have recently made changes to their positions in the stock. M&T Bank Corp acquired a new stake in shares of Catalent during the first quarter worth approximately $207,000. Forward Management LLC boosted its stake in shares of Catalent by 8.7% in the first quarter. Forward Management LLC now owns 17,656 shares of the company’s stock worth $471,000 after buying an additional 1,411 shares during the period. Royal Bank of Canada boosted its stake in shares of Catalent by 81.5% in the first quarter. Royal Bank of Canada now owns 34,988 shares of the company’s stock worth $933,000 after buying an additional 15,706 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Catalent by 45.2% in the first quarter. Envestnet Asset Management Inc. now owns 38,974 shares of the company’s stock worth $1,039,000 after buying an additional 12,141 shares during the period. Finally, UBS Group AG boosted its stake in shares of Catalent by 1.1% in the first quarter. UBS Group AG now owns 66,308 shares of the company’s stock worth $1,769,000 after buying an additional 712 shares during the period. Hedge funds and other institutional investors own 99.72% of the company’s stock.
Shares of Catalent (NYSE:CTLT) opened at 25.84 on Friday. The stock has a market cap of $3.22 billion, a P/E ratio of 29.03 and a beta of 1.41. The stock has a 50 day moving average of $25.22 and a 200 day moving average of $25.66. Catalent has a one year low of $18.92 and a one year high of $32.24.
Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.
Receive News & Stock Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related stocks with our FREE daily email newsletter.